Apricus Biosciences’ (APRI) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Apricus Biosciences, Inc (NASDAQ:APRI) in a research note released on Wednesday morning. The brokerage currently has a $5.00 target price on the stock.
Separately, Zacks Investment Research cut shares of Apricus Biosciences from a hold rating to a sell rating in a research note on Friday, August 4th.
Apricus Biosciences (APRI) opened at 1.56 on Wednesday. The company has a market cap of $19.94 million, a PE ratio of 2.60 and a beta of 0.54. The stock has a 50 day moving average of $1.34 and a 200 day moving average of $1.57. Apricus Biosciences has a 12-month low of $0.86 and a 12-month high of $4.94.
Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Wednesday, August 2nd. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Equities analysts expect that Apricus Biosciences will post ($0.81) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Apricus Biosciences’ (APRI) “Buy” Rating Reiterated at HC Wainwright” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/02/apricus-biosciences-apri-buy-rating-reiterated-at-hc-wainwright.html.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Stock Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related stocks with our FREE daily email newsletter.